Tekla Capital Management LLC acquired a new stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 70,000 shares of the biopharmaceutical company’s stock, valued at approximately $747,000. Tekla Capital Management LLC owned about 0.07% of Lexicon Pharmaceuticals at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Tocqueville Asset Management L.P. purchased a new stake in shares of Lexicon Pharmaceuticals during the second quarter valued at $164,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Lexicon Pharmaceuticals during the second quarter valued at $205,000. GSA Capital Partners LLP grew its holdings in shares of Lexicon Pharmaceuticals by 321.7% during the third quarter. GSA Capital Partners LLP now owns 74,586 shares of the biopharmaceutical company’s stock valued at $796,000 after buying an additional 56,900 shares during the last quarter. Bank of Montreal Can grew its holdings in shares of Lexicon Pharmaceuticals by 8,364.1% during the third quarter. Bank of Montreal Can now owns 122,053 shares of the biopharmaceutical company’s stock valued at $1,302,000 after buying an additional 120,611 shares during the last quarter. Finally, First Trust Advisors LP purchased a new stake in shares of Lexicon Pharmaceuticals during the third quarter valued at $1,525,000.
NASDAQ:LXRX opened at $7.44 on Wednesday. Lexicon Pharmaceuticals, Inc. has a one year low of $7.04 and a one year high of $13.97. The company has a debt-to-equity ratio of 8.85, a quick ratio of 2.83 and a current ratio of 2.90. The firm has a market capitalization of $858.00 million, a price-to-earnings ratio of -5.86 and a beta of 0.75.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.07. Lexicon Pharmaceuticals had a negative net margin of 168.23% and a negative return on equity of 1,247.65%. The company had revenue of $6.90 million for the quarter, compared to analyst estimates of $12.56 million. During the same period in the prior year, the company earned ($0.29) earnings per share. The firm’s revenue was down 74.3% on a year-over-year basis. Sell-side analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -1.29 earnings per share for the current year.
A number of brokerages have recently weighed in on LXRX. BidaskClub lowered shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday. Zacks Investment Research lowered shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 7th. ValuEngine lowered shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 17th. Cowen reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Friday, November 2nd. Finally, Gabelli reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Friday, November 2nd. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the stock. Lexicon Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $25.25.
COPYRIGHT VIOLATION WARNING: “Tekla Capital Management LLC Acquires New Holdings in Lexicon Pharmaceuticals, Inc. (LXRX)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/12/05/tekla-capital-management-llc-acquires-new-holdings-in-lexicon-pharmaceuticals-inc-lxrx.html.
Lexicon Pharmaceuticals Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
See Also: Ex-Dividend
Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX).
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.